Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Executive Summary

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.

You may also be interested in...



DTC For Accelerated Approval Drugs: US FDA Is Taking Another Look At Disclosure On Websites

Study will assess responses of cancer survivors and caregivers to disclosures that a drug received accelerated approval. FDA analysis found that 73% of 26 accelerated approval drugs cited approval pathway on product websites.

Do Consumers Understand TV Ads For Oncology Drugs?

US FDA plans to conduct a study to evaluate consumer comprehension of oncology indications in direct-to-consumer television advertising.

US FDA Advertising Citations Remain Rare In 2018

With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS122697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel